Nicox S.A.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutics to maintain vision and improve ocular health. The company's primary business involves creating and advancing a pipeline of investigational drugs for ophthalmological diseases. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop in development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. Nicox advances its portfolio through in-house research and strategic partnerships with other pharmaceutical companies for clinical development and commercialization.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Nicox S.A..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-12 15:53 |
Declaration of Voting Results & Voting Rights Announcements
Franchissement de seuils
|
French | 113.6 KB | |
| 2025-08-08 07:30 |
Share Issue/Capital Change
Nicox Extends Existing Flexible Equity Financing
|
English | 181.9 KB | |
| 2025-08-05 07:30 |
Regulatory News Service
Nicox annonce l’initiation par son partenaire Kowa d’un essai clinique de Phase…
|
French | 176.0 KB | |
| 2025-08-05 07:30 |
Regulatory News Service
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
|
English | 171.5 KB | |
| 2025-06-30 07:30 |
Earnings Release
Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Dena…
|
French | 161.2 KB | |
| 2025-06-30 07:30 |
Regulatory News Service
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
|
English | 156.1 KB | |
| 2025-06-06 07:30 |
Pre-Annual General Meeting Information
Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 27 ju…
|
French | 184.6 KB | |
| 2025-06-06 07:30 |
Pre-Annual General Meeting Information
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 2…
|
English | 175.2 KB | |
| 2025-05-27 07:30 |
Earnings Release
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX…
|
English | 179.6 KB | |
| 2025-05-27 07:30 |
Earnings Release
Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Ko…
|
French | 183.6 KB | |
| 2025-05-14 07:30 |
Earnings Release
Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans l…
|
French | 199.5 KB | |
| 2025-05-14 07:30 |
Regulatory News Service
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
|
English | 184.4 KB | |
| 2025-04-30 07:30 |
Earnings Release
Nicox Provides Full Year 2024 Financial Results
|
English | 181.9 KB | |
| 2025-04-30 07:30 |
Earnings Release
Nicox : Résultats financiers de l’année 2024
|
French | 180.4 KB | |
| 2025-03-19 07:30 |
Legal Proceedings Report
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler…
|
English | 218.6 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
